GHK-Cu Skin Research: Two New 2026 Papers, and Why Their Design Differs

Two GHK-Cu papers, the copper tripeptide that also shows up as copper tripeptide-1, landed in 2026 within a few weeks of each other. Both point to anti-inflammatory effects in skin-related models. Past that overlap, they barely line up at all, and the gap between them is a good reminder of what to check when you read this slice of the literature.

Start with the basic symmetry: neither group tested GHK-Cu as the main standalone intervention. In both cases it sits inside a two-part mix, and the headline results are about the mix.

The cosmetics company study

In August 2026, Skin Research and Technology published work from the Global R&D Center of Shanghai Chicmax Cosmetic Co. Ltd. Their focus was a mixed-culture ferment extract from Thermus thermophilus and Bacillus subtilis, labeled TBFE, paired with GHK-Cu.

They present the evidence in three tiers, cell experiments, ex vivo skin explants, and a clinical component.

In vitro, macrophages were stimulated with lipopolysaccharide, and the readout was inflammatory cytokine secretion. The authors report that the TBFE, GHK-Cu combination suppressed cytokines more than TBFE alone or GHK-Cu alone. Next came ex vivo testing: a face cream whose only active ingredients were that same pairing was applied to human skin explants exposed to UV. They report protection against UV-induced damage, described as better preservation of skin morphology plus less extracellular matrix degradation. Finally, in the clinical portion, they report that the combination reduced wrinkles and improved barrier condition.

Their takeaway is a broad one: the formulation acts on inflammation, extracellular matrix integrity, and barrier function at the same time.

Here the affiliation is not a footnote detail. All four authors list the Global R&D Center of the same company that made the formulation being tested. The manuscript also states that there are no conflicts of interest. Those two facts, the affiliation and the disclosure, both belong in any honest summary, and readers can judge what weight they give them.

The university study

The other paper appeared earlier, late June 2026, in Antioxidants. It came from Yonsei University, with a co-author from Hannam University. The design is different, and so is the partner ingredient.

This team made a complex using Torilis japonica extract, shortened to TJE, combined with GHK-Cu. They tested it in HaCaT keratinocytes stimulated with TNF-alpha and interferon gamma. They report that TJE lowered expression of the chemokines TARC and CTACK and reduced IgE production, and that an “optimised” 6:4 ratio of TJE to GHK-Cu showed the strongest activity compared with either component alone. They interpret that pattern as evidence of synergy.

They also report suppressed transcription of IL-4, IL-5, IL-10, and IL-13, improved keratinocyte migration in wound-healing assays, and radical scavenging activity without harming cell viability. Their conclusion is cautious: a formulation that merits more work.

This paper includes a funding statement saying the funders were not involved in the design, data collection, analysis, interpretation, writing, or publication decision.

What neither GHK-Cu study actually nails down

Both studies are worth reading, but the same boundary runs through both: neither is a single-agent test of GHK-Cu.

In each case, the central claim is “the combination beats its parts.” That is a statement about a pairing. It is not the same as showing that the peptide alone produces the full effect. If someone walks away with a simplified line like “GHK-Cu reduces inflammatory cytokines” based on either paper, they have tightened the finding beyond what is being tested.

The model choice matters just as much. Macrophage and keratinocyte systems are cell models. Skin explants are pieces of tissue, not a living person. The only human element in the Chicmax paper is a cosmetics-style outcome assessment, which answers a different question than a mechanistic experiment on a purified compound.

None of that makes either paper bad at what it set out to do. It does mean the results are, in practice, results for specific formulations under specific conditions, and anything more general is an inference made by the reader, not something the authors established.

Affiliations show up in the background literature too

When people argue the mechanistic case for GHK-Cu in skin, they often point back to a 2018 International Journal of Molecular Sciences review by Pickart and Margolina. That review describes the peptide as promoting blood vessel and nerve outgrowth, boosting collagen, elastin, and glycosaminoglycan synthesis, and supporting dermal fibroblast function, alongside a long list of protective effects across tissues.

It is a standard citation, and it deserves the same disclosure-minded reading. Both authors list R&D Skin Biology, a company operating in the space. The review’s framing is also unusually expansive, describing the peptide’s many biological actions as all appearing to be health-positive, which is a strong posture for a molecule whose evidence base is still heavily weighted toward cell and animal work.

Anyone specifically interested in gene-expression findings will do better starting from our overview of how GHK-Cu affects gene expression, which goes into more detail than the broad review summary.

Why this way of reading pays off

Most of the peptide claims that circulate online can be filtered with three quick checks, and it helps to do them before you get pulled into the results.

First, who ran the study, and whose product was tested. Not as a moral judgement, just as context for how much independent replication still matters.

Second, was the compound tested on its own or as part of a blend. If “synergy” is the headline, the claim is about the pair, and it tells you less about either ingredient than a clean single-agent experiment would.

Third, what kind of model was used. Cell culture, explant tissue, and human cosmetic endpoints each answer different questions, and you cannot simply move results up that ladder without new experiments.

For labs planning work in this area, the practical side is covered in our guide to sourcing GHK-Cu for laboratory use in Europe. As for these two 2026 papers, it is simplest to read them as they are: formulation studies placing GHK-Cu next to another active ingredient and reporting what the pair does.

References

1. Wang J, Tao K, Huang H, Chang H. Augmented Skin Beneficial Effects of Thermus Thermophilus and Bacillus Subtilis Mixed-Culture Ferment Extract by Tripeptide GHK-Cu. Skin Res Technol. 2026;32(8):e70360. https://pubmed.ncbi.nlm.nih.gov/42573538/ · https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13455814/
2. Jeon S, Maeng J, Lee J, Kim YM, Nam G. A Torilis japonica Extract-GHK-Cu Complex Attenuates Th2 Cytokines and Promotes Keratinocyte Recovery: A Potential Antioxidant Strategy for Atopic Dermatitis. Antioxidants (Basel). 2026;15(7):818. https://pubmed.ncbi.nlm.nih.gov/42510549/
3. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. https://pubmed.ncbi.nlm.nih.gov/29986520/

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.